Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma

Fabio Bozzi, Paola Collini, Antonella Aiello, Elena Barzanò, Felicita Gambirasio, Marta Podda, Cristina Meazza, Andrea Ferrari, Roberto Luksch

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The goal of this study was to develop a flow cytometric (FCM) method for assessing the presence of metastatic cells in bone marrow (BM) and peripheral blood (PB) obtained from rhabdomy'sarcoma (RMS) patients. Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored. Patients and Methods: CD45, CD56, CD90 and CD57 antibodies were used in 7 paired BM and PB samples (from 7 RMS stage TV patients at presentation), 23 BM samples (from 13 RMS stage I and II patients at presentation), and ten paired BM and PB samples taken at presentation and five BM samples taken at recurrence from 13 NB stage 4 patients. Results: All seven BM samples from RMS stage IV (but not those from patients with localized disease) showed both the CD45- CD56+ phenotype and the Myf4 transcript. Four cases also showed CD90 and two CD57 positivity. Neither the CD45-CD56+ phenotype, nor Myf4 were recorded in the BM and PB samples from patients with localized disease. All the NB BM samples (15/15) showed the CD45- CD56+ CD90+ phenotype and 10/15 also showed CD57 positivity. Only 3/10 blood samples from the NB patients revealed tumor cells. Conclusion: CD45, CD56, CD90 and CD57 antibodies can be used in FCM for marrow metastasis detection in both, RMS and NB patients.

Original languageEnglish
Pages (from-to)1565-1569
Number of pages5
JournalAnticancer Research
Volume28
Issue number3 A
Publication statusPublished - May 2008

Fingerprint

Rhabdomyosarcoma
Neuroblastoma
Bone Marrow Cells
Differential Diagnosis
Bone Marrow
Phenotype
Sarcoma
Myogenin
Antibodies
Neoplasm Metastasis
Recurrence

Keywords

  • Flow cytometry
  • Immunophenotyping
  • Neuroblastoma
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma. / Bozzi, Fabio; Collini, Paola; Aiello, Antonella; Barzanò, Elena; Gambirasio, Felicita; Podda, Marta; Meazza, Cristina; Ferrari, Andrea; Luksch, Roberto.

In: Anticancer Research, Vol. 28, No. 3 A, 05.2008, p. 1565-1569.

Research output: Contribution to journalArticle

@article{0765b563b8f04d868d98015a8eedbfbc,
title = "Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma",
abstract = "Background: The goal of this study was to develop a flow cytometric (FCM) method for assessing the presence of metastatic cells in bone marrow (BM) and peripheral blood (PB) obtained from rhabdomy'sarcoma (RMS) patients. Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored. Patients and Methods: CD45, CD56, CD90 and CD57 antibodies were used in 7 paired BM and PB samples (from 7 RMS stage TV patients at presentation), 23 BM samples (from 13 RMS stage I and II patients at presentation), and ten paired BM and PB samples taken at presentation and five BM samples taken at recurrence from 13 NB stage 4 patients. Results: All seven BM samples from RMS stage IV (but not those from patients with localized disease) showed both the CD45- CD56+ phenotype and the Myf4 transcript. Four cases also showed CD90 and two CD57 positivity. Neither the CD45-CD56+ phenotype, nor Myf4 were recorded in the BM and PB samples from patients with localized disease. All the NB BM samples (15/15) showed the CD45- CD56+ CD90+ phenotype and 10/15 also showed CD57 positivity. Only 3/10 blood samples from the NB patients revealed tumor cells. Conclusion: CD45, CD56, CD90 and CD57 antibodies can be used in FCM for marrow metastasis detection in both, RMS and NB patients.",
keywords = "Flow cytometry, Immunophenotyping, Neuroblastoma, Rhabdomyosarcoma",
author = "Fabio Bozzi and Paola Collini and Antonella Aiello and Elena Barzan{\`o} and Felicita Gambirasio and Marta Podda and Cristina Meazza and Andrea Ferrari and Roberto Luksch",
year = "2008",
month = "5",
language = "English",
volume = "28",
pages = "1565--1569",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma

AU - Bozzi, Fabio

AU - Collini, Paola

AU - Aiello, Antonella

AU - Barzanò, Elena

AU - Gambirasio, Felicita

AU - Podda, Marta

AU - Meazza, Cristina

AU - Ferrari, Andrea

AU - Luksch, Roberto

PY - 2008/5

Y1 - 2008/5

N2 - Background: The goal of this study was to develop a flow cytometric (FCM) method for assessing the presence of metastatic cells in bone marrow (BM) and peripheral blood (PB) obtained from rhabdomy'sarcoma (RMS) patients. Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored. Patients and Methods: CD45, CD56, CD90 and CD57 antibodies were used in 7 paired BM and PB samples (from 7 RMS stage TV patients at presentation), 23 BM samples (from 13 RMS stage I and II patients at presentation), and ten paired BM and PB samples taken at presentation and five BM samples taken at recurrence from 13 NB stage 4 patients. Results: All seven BM samples from RMS stage IV (but not those from patients with localized disease) showed both the CD45- CD56+ phenotype and the Myf4 transcript. Four cases also showed CD90 and two CD57 positivity. Neither the CD45-CD56+ phenotype, nor Myf4 were recorded in the BM and PB samples from patients with localized disease. All the NB BM samples (15/15) showed the CD45- CD56+ CD90+ phenotype and 10/15 also showed CD57 positivity. Only 3/10 blood samples from the NB patients revealed tumor cells. Conclusion: CD45, CD56, CD90 and CD57 antibodies can be used in FCM for marrow metastasis detection in both, RMS and NB patients.

AB - Background: The goal of this study was to develop a flow cytometric (FCM) method for assessing the presence of metastatic cells in bone marrow (BM) and peripheral blood (PB) obtained from rhabdomy'sarcoma (RMS) patients. Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored. Patients and Methods: CD45, CD56, CD90 and CD57 antibodies were used in 7 paired BM and PB samples (from 7 RMS stage TV patients at presentation), 23 BM samples (from 13 RMS stage I and II patients at presentation), and ten paired BM and PB samples taken at presentation and five BM samples taken at recurrence from 13 NB stage 4 patients. Results: All seven BM samples from RMS stage IV (but not those from patients with localized disease) showed both the CD45- CD56+ phenotype and the Myf4 transcript. Four cases also showed CD90 and two CD57 positivity. Neither the CD45-CD56+ phenotype, nor Myf4 were recorded in the BM and PB samples from patients with localized disease. All the NB BM samples (15/15) showed the CD45- CD56+ CD90+ phenotype and 10/15 also showed CD57 positivity. Only 3/10 blood samples from the NB patients revealed tumor cells. Conclusion: CD45, CD56, CD90 and CD57 antibodies can be used in FCM for marrow metastasis detection in both, RMS and NB patients.

KW - Flow cytometry

KW - Immunophenotyping

KW - Neuroblastoma

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=45949093849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949093849&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 1565

EP - 1569

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -